Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
S
S

Sanofi


Balita

France corporate earnings week ahead

DIARY-France corporate earnings week ahead July 19 (Reuters) - Diary of France (.FCHI) corporate earnings for the week ahead FRANCE EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 23-Jul-2024 AMC LVMH.PA LVMH Moet Hennessy Louis Vuitton SE Half Year 2024 LVMH Moet Hennessy Louis Vuitton SE Earnings Release 23-Jul-2024 BMO EDEN.PA Edenred SE Half Year 2024 Edenred SE Earnings Release 23-Jul-2024 05:00 TCFP.PA Thales SA Half Year 2024 Thales SA Earnings Release 24-Jul-2024 AMC CAR
A
B
B
C
C
D
E
E
H
K
L
O
R
S
T
V
V
A
F

Sanofi's Consumer Arm Said To Draw Bids From Advent, Pai, CD&R ; Bids Value Business At Up To Eur 15 Bln - Bloomberg News

BRIEF-Sanofi's Consumer Arm Said To Draw Bids From Advent, Pai, CD&R ; Bids Value Business At Up To Eur 15 Bln - Bloomberg News July 17 (Reuters) - Sanofi SA SASY.PA : SANOFI’S CONSUMER ARM SAID TO DRAW BIDS FROM ADVENT, PAI, CD&R ; BIDS VALUE BUSINESS AT UP TO EUR 15 BILLION - BLOOMBERG NEWS Source : https://tinyurl.com/3ntmm7cu
S

Sanofi to invest $437 mln in India global centre, double its workforce

Sanofi to invest $437 mln in India global centre, double its workforce By Rishika Sadam HYDERABAD, July 17 (Reuters) - French drugmaker Sanofi SASY.PA plans to invest 400 million euros ($437.24 million) in its global capacity centre (GCC) in India by the end of the decade, as it aims to expand and more than double its workforce over the next two years, a top company executive said on Wednesday.
S

EU court criticises Commission over handling of COVID vaccine contracts

UPDATE 3-EU court criticises Commission over handling of COVID vaccine contracts Adds more reaction from Commission in paragraphs 8-10 By Foo Yun Chee and Bart H. Meijer BRUSSELS, July 17 (Reuters) - Europe's second-highest court on Wednesday criticised the European Commission for a lack of transparency over COVID-19 vaccine contracts four years ago, a day before a key vote on Commission head Ursula von der Leyen's bid for a second term.
A
P
S

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch July 16 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. EUROFINS EUFI.PA The Luxembourg-based firm on Monday said it opposed the decision by its competitor SGS to call off a planned sale of its crop science unit.
E
L
S
S
F
N
U

Danone expects Olympics sales boost after revamping brands ahead of Games

Danone expects Olympics sales boost after revamping brands ahead of Games By Richa Naidu LONDON, July 15 (Reuters) - Olympics sponsor Danone DANO.PA is expecting both a short and longer-term sales boost from the Games, having made changes to its products, invested in branding, and positioned itself in physical kiosks across Paris, its CEO said. Danone, which makes Activia yoghurt, Evian water and Silk plant-based drinks, first reached out to the International Olympic Committee in mid-2022 to get
D
L
S
C

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

UPDATE 1-Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market Adds response from Shaheen's office in paragraph 5 By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 12 (Reuters) - Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
S

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market

Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market By Maggie Fick and Ahmed Aboulenein LONDON/WASHINGTON, July 12 (Reuters) - Democratic U.S. Senate aides will meet with Novo Nordisk executives on Tuesday to discuss fallout from its decision to stop selling one of its long-acting insulins in the country, two sources familiar with the meeting told Reuters.
S

Banks Plan 6 Billion Euro Debt Financing For Sanofi Consumer Sale- Bloomberg News

BRIEF-Banks Plan 6 Billion Euro Debt Financing For Sanofi Consumer Sale- Bloomberg News July 12 (Reuters) - BANKS PLAN €6 BILLION DEBT FINANCING FOR SANOFI CONSUMER SALE- BLOOMBERG NEWS Source https://tinyurl.com/yc8rv8bh
B
G
S

EMA's PRAC Says Could Not Establish A Causal Association Between 1 Analogues And Aspiration

BRIEF-EMA's PRAC Says Could Not Establish A Causal Association Between GLP-1 Analogues And Aspiration July 12 (Reuters) - EMA's PRAC: EMA'S PRAC: NEW RECOMMENDATIONS FOR GLP-1 RECEPTOR AGONISTS TO MINIMISE RISK OF ASPIRATION & PNEUMONIA ASPIRATION IN GENERAL ANAESTHESIA/DEEP SEDATION EMA'S PRAC: PATIENTS TREATED WITH GLP-1 MEDICINES SHOULD INFORM T
A
S

US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices

UPDATE 1-US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices Adds Novo Nordisk's responses in paragraphs 6-7 and 22 By Ahmed Aboulenein WASHINGTON, July 10 (Reuters) - Senator Bernie Sanders on Wednesday expressed confidence that Novo Nordisk NOVOb.CO can be convinced to cut the U.S. prices of its popular Ozempic and Wegovy drugs used for weight loss by publicly shaming the company over how much it charges compared with prices in other countries.
S

Sanofi Ships U.S. Influenza Vaccines For The 2024/25 Season

BRIEF-Sanofi Ships U.S. Influenza Vaccines For The 2024/25 Season Sanofi SA SASY.PA : SANOFI SHIPS U.S. INFLUENZA VACCINES FOR THE 2024/25 SEASON SANOFI - ADDITIONAL SHIPMENTS OF FULL SANOFI FLU VACCINE PORTFOLIO WILL CONTINUE THROUGH OCTOBER Source text for Eikon: ID:nPn6wmY2Pa Further company coverage: SASY.PA
S

CVS Health, Cigna down after report FTC to sue PBMs over insulin prices

BUZZ-CVS Health, Cigna down after report FTC to sue PBMs over insulin prices ** Shares of health insurers fall; CVS Health CVS.N down ~1% at $57.05 and Cigna CI.N slips 0.8% to $325.88 ** The U.S. Federal Trade Commission (FTC) plans to sue pharmacy-benefit managers (PBMs) CVS Health, Cigna and UnitedHealth UNH.N , a source familiar with the matter told Reuters ** The FTC is suing the companies over their tactics for negotiating prices for drugs, including insulin - source ** The FTC is also loo
C
S

US FTC to sue drug middlemen over insulin prices, source says

UPDATE 5-US FTC to sue drug middlemen over insulin prices, source says Adds Novo declining comment, background on insulin By Jody Godoy and Mariam Sunny July 10 (Reuters) - The U.S. Federal Trade Commission is planning to sue UnitedHealth UNH.N , Cigna CI.N and CVS Health CVS.N over their tactics as middlemen in negotiating prices for drugs including insulin, a person familiar with the matter s aid on Wednesday.
C
S

Kymera rises, partner Sanofi to expand trials for inflammatory disease drug

BUZZ-Kymera rises, partner Sanofi to expand trials for inflammatory disease drug ** Shares of Kymera Therapeutics KYMR.O up 12.6% at $36 after the bell ** The drug developer says partner Sanofi SASY.PA plans to expand ongoing mid-stage studies for experimental drug to treat Hidradenitis Suppurativa, a chronic inflammatory skin condition, and Atopic
S

Pharma partnerships brewing for assisted drug discovery efforts, Jefferies says

BUZZ-Pharma partnerships brewing for AI-assisted drug discovery efforts, Jefferies says ** Pharma companies are accelerating partnerships across AI landscape to start "leveraging early innings of AI-assisted drug discovery efforts" - brokerage Jefferies ** AI may have power to improve success, reduce risk and lower costs in drug development in the
S

Bpifrance eyes investment in Sanofi's consumer health business

Bpifrance eyes investment in Sanofi's consumer health business July 4 (Reuters) - Bpifrance Executive Director Jose Gonzalo said that the public investment bank is considering a potential investment in Sanofi's SASY.PA consumer health unit, Bloomberg News reported on Thursday. The French public investment bank is in talks with "many funds" and may team up with the winning bidder for Sanofi's consumer health unit, Gonzalo was quoted as saying.
S

EU approves Sanofi's Dupixent for 'smoker's lungs'

EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi SASY.PA and partner Regeneron REGN.O on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States. The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a re
R
S

Adyen, AstraZeneca, Auto Trader

EUROPE RESEARCH ROUNDUP-Adyen, AstraZeneca, Auto Trader July 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Adyen, AstraZeneca and Auto Trader, on Tuesday. HIGHLIGHTS * Adyen NV ADYEN.AS : Jefferies cuts target price to EUR 1,695 from EUR 1,821 * AstraZeneca AZN.L : Jefferies raises target price to 11,700p from 11,300p * Auto Trader AUTOA.L : Jefferies raises target price to 935p from 830p * Halma HLMA.L : HSBC raises target pri
3
A
A
A
B
C
C
C
E
E
E
G
H
R
S
S
V
A
A
A
A
A
B
N
N
S

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge

Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge By Brendan Pierson July 1 (Reuters) - A Delaware judge rebuffed a request by GSK GSK.L and other drugmakers to appeal a ruling allowing more than 70,000 lawsuits claiming that the heartburn drug Zantac caused cancer to go forward. The ruling by Judge Vivian Medinilla of the Delaware Superior Court means that the drugmakers, which also include Pfizer PFE.N , Sanofi SASY.PA and Boehringer Ingelheim, will have to ask the Delaware Su
G
P
S



Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.